News

Other news

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.

By JLABS

Read full story
Other news

Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment

By JLABS

Read full story
Other news

Calypso Biotech BV secures 20 Million EUR in Series A Financing to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases

By JLABS

Read full story
Other news

Genome Biologics wins prestigious Horizon 2020 EU Phase 2 grant award

By JLABS

Read full story
Other news

Knowledge for Growth 2018 Recap

By Janssen Belgium

Read full story
Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story
Other news

Next stop, Europe! @JNJInnovation introduces @JLABS in Belgium

By JLABS

Read full story